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Abstract
Serum polychlorinated biphenyls (PCBs) in Anniston, AL, residents have been associated with hypertension and diabetes. There have been no systematic
interventions to reduce PCB body burdens in Anniston or other populations. Our objective was to determine the efficacy of 15 g/day of dietary olestra to reduce
PCBs in Anniston residents. Blood PCBs and 1,1-bis-(4-chlorophenyl)-2,2-dichloroethene were measured at baseline and 4-month intervals in a double-blind,
placebo-controlled, 1-year trial. Participants with elevated serum PCBs were randomized into two groups of 14 and received potato crisps made with olestra or
vegetable oil (VO). Elimination rates during the study period were compared with 5-year prestudy rates. Eleven participants in the olestra group and 12 in the
VO group completed the study. Except for one participant in the VO group, reasons for dropout were unrelated to treatments. The elimination rate of 37 noncoplanar PCB congeners during the 1-year trial was faster during olestra consumption compared to the pretrial period (−0.0829±0.0357 and −0.00864±0.0116
year−1, respectively; P=.04), but not during VO consumption (−0.0413±0.0408 and −0.0283±0.0096 year−1, respectively; P=.27). The concentration of PCBs
in two olestra group participants decreased by 27% and 25% during the trial. There was no significant time by group interaction in change from baseline.
However, group main effects for total PCBs and PCB 153 were of borderline significance. This pilot study has demonstrated that olestra can safely reduce body
burdens of PCBs and supports a larger intervention trial that may also determine whether reduction in PCBs will reduce the risk of hypertension and diabetes.
© 2014 Elsevier Inc. All rights reserved.
Keywords: PCBs DDE; Olestra; Dietary intervention

1. Introduction
Abbreviations: DDE, 1,1-bis-(4-chlorophenyl)-2,2-dichloroethene; PCB,
polychlorinated biphenyl; ACHS, Anniston Community Health Survey.
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Polychlorinated biphenyls (PCBs) are persistent, environmental
toxicants and/or carcinogens. PCBs were manufactured for 40 years in
Anniston, AL, resulting in environmental contamination and high
body burdens of PCBs that were associated with increased risk of
hypertension and diabetes as assessed by the Anniston Community
Health Study (ACHS) [1–3]. No systematic interventions have been
made to reduce PCBs in Anniston residents.
In addition to the studies in Anniston, the analysis of NHANES data
disclosed a strong association between the serum level of non-coplanar
PCB 153 and diabetes [4]. Although there is an apparent relationship
between risk of disease and level of PCBs, there is minimal evidence that
reducing the levels of PCBs will alter this risk. To our knowledge, only a
single case report study has demonstrated that reducing PCBs will
reduce the markers of disease, specifically blood glucose and lipid levels
[5]. Presumably, this paucity of data is the result of not having a suitable
method for removing PCBs from the body. We therefore undertook the
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study to determine if it is possible to reduce PCB levels as a first step
toward determining whether disease risk might then be altered.
PCBs are lipophilic and associated with stored triglycerides and serum
lipids. The concentration of PCB levels in serum lipids thus reflects the
total body burden as an estimate of the concentration in adipose tissue
[6–8]. The measurements of PCBs in Anniston residents noted above have
utilized lipid-corrected serum levels as a measure of exposure. Although
direct measurements of concentration in adipose tissue and total body fat
would have provided a more exact determination of body burden, we
opted to use the lipid-normalized serum levels because of concerns
about participant compliance in this exploratory trial.
PCBs and their metabolites enter the intestine by biliary or
nonbiliary secretion and are reabsorbed by enterohepatic circulation.
Reducing organochlorine reabsorption hastens removal from the
body as demonstrated by administering cholestyramine to remove
kepone [9]. Following the same strategy, we used the nonabsorbable
lipid olestra, which reduces 1,1,1-trichloro-2,2'-bis(4-chlorophenyl)
ethane (DDT) absorption and enhances 1,1-bis-(4-chlorophenyl)-2,2dichloroethene (DDE) excretion in animals [10,11]. When added to
the diet of mice exposed to hexachlorobenzene (HCB), olestra
increased HCB excretion 30-fold [12]. Remarkably, in a study of a
single patient who had high PCB exposure, a regimen of olestra
decreased adipose PCBs from 3200 to 56 mg/kg over 2 years [5].
These previous preliminary studies have demonstrated that olestra
can increase the rate of excretion of organochlorines from the body.
However, there has not been a controlled randomized clinical trial to
determine if olestra is effective in reducing the body burden of
organochlorines in humans. In addition to the preliminary data that
demonstrated effects of olestra on organochlorines in animals, we
believed that olestra would provide a low-risk dietary intervention
with high probability of compliance during a year of study.
Olestra is approved by the Food and Drug Administration for use in
foods in the United States, and it is also approved for food uses in 24
other countries. Potato crisps of uniform size containing olestra
provide a readily measurable dose form. We report here the results of
a 1-year placebo-controlled intervention with olestra to reduce PCBs
in residents of Anniston, AL. In addition to the measurement of
changes in serum PCBs, we measured serum DDE levels, which had
been previously reported to be reduced by olestra in animals [11].
2. Subjects and methods
2.1. Study participants
Study participants from Anniston were identified from the ACHS
with serum PCB levels (37 non-coplanar congeners) above the
national 50th percentile reported in the 2005–2007 National Health
and Nutrition Examination Survey [13]. Recruitment from this pool
ensured measurement of PCB levels during the trial and during the 4–
6-year period prior to the trial. Recruitment took place from
December 2010 to March 2011. All participants began the trial on
April 27 or April 28, 2011.
The study size was based on the expected standard deviation of
4.5% for within-group error for PCB analyses [14]. A group size of 10,
80% power and alpha of 0.05 predicted that we would be able to see a
reduction in body burden in the olestra group of 7% relative to a 1%
change in the control group in a year. We recruited 14 participants in
each group with the goal of completing the parallel trial with 10 in
each group.
Exclusion criteria included pregnancy, lactation, intolerance of the
test products, current use of weight-loss medications, gastrointestinal
or eating disorders, history of bariatric surgery and kidney stones. All
participants were given verbal and written explanation of the study,
questions concerning its risks and details were solicited, and written
informed consent statement was obtained.

2.2. Test products
Crisps made with either olestra or vegetable oil (VO) were
purchased commercially. Olestra crisps were Pringles Light Original,
and VO crisps were Pringles Original. Both crisps were then produced by
Procter & Gamble and are now produced by Kellogg. The daily dose of 24
olestra crisps provided 15 g of olestra. The crisps were provided in
individually sealed and labeled packets that contained half of the daily
dose (12 olestra crisps; 6 VO crisps). The dose of both crisps provided
112 kcal/day. A month’s supply of crisps was packaged in a sealed
opaque box, and the study coordinator who dispensed the boxes was
not aware of the contents. The participants were also unaware of their
treatment assignment. Participants recorded daily ingestion of crisps in
diaries, and they returned boxes containing unused product. Compliance was assessed as percent of provided dose.
2.3. Study design
Participants were randomized a priori by the Cincinnati Children’s
Hospital biostatistician into VO and olestra groups of 14 each and
enrolled using a stratified design based on body mass index (BMI)
split at 30 kg/m2 and sex. Within each stratum, the subjects were put
in random order using a random number generator in SAS. Then,
group assignment was generated using random block sizes of 2 and 4
due to the small sample size.
Subjects visited the Anniston clinical site monthly for 12 months.
Every 2 months, they were weighed, received nutritional counseling
and were given a 2-month supply of crisps. At each visit, participants
returned diaries recording crisp consumption. At months 0, 4, 8 and
12, fasting blood samples were taken for PCB and lipid analyses.
Serum glucose and insulin were measured at 0 and 12 months.
The study was approved by Institutional Review Board (IRB) of
the Cincinnati Children’s Hospital Medical Center. This study
included use of a US Food and Drug Administration’s Investigational
New Drug Application (IND #109 636) for olestra-containing crisps.
At the Centers for Disease Control and Prevention (CDC), analyses
were conducted as technical assistance and in compliance with
Research Determination procedure; an exemption from the CDC IRB
was obtained. Data collection in the original ACHS was approved by
the IRB of the University of Alabama at Birmingham. The study is
registered with ClinicalTrials.gov (NCT01261338). Adverse events
were reported to the Anniston Coordinator, and a medical
consultant in Anniston was available at all times to evaluate any
report of referral for medical care.
2.4. Serum measurements
Serum lipids were measured using a CDC-certified method
(Medpace Reference Laboratories, Cincinnati, OH). Serum glucose
(Trinder modified Emerson method), insulin (radioimmunoassay)
and vitamin E (high-performance liquid chromatography) were
measured at the CTRC Core Laboratory, Cincinnati Children’s Hospital
Medical Center, Cincinnati, OH.
2.5. Organochlorine analysis
Serum was analyzed for PCB non-coplanar congeners, consisting of
35 individual congeners and 2 sets of coeluting peaks (congeners
138–158 and 196–203), at the CDC as described previously [14]. This
set of congeners was previously studied in the Anniston ACHS and
allowed us to utilize pretrial concentrations from that study. The
method also provided measurements of nine pesticides including
DDE, and we analyzed DDE in addition to the PCBs. PCB and DDE
concentrations were normalized to serum lipids as previously
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described (2.27×total cholesterol+triglycerides+62.3) and
expressed as ng/g lipid [6–8].

Table 1
Baseline characteristics of the participants who started the study
Variable

Olestra n=14

VO n=14

P value

2.6. Statistical considerations

Age (years)
Female
Race/ethnicity
African American
White
Native American
BMI
Total cholesterol (mg/dl)
LDL cholesterol (mg/dl)
HDL cholesterol (mg/dl)
Triglycerides (mg/dl)
Glucose (mg/dl)
Insulin (U/ml)
α-Tocopherol (μg/ml)

59.9±2.6
8 (57.1%)

61.0±1.5
9 (64.3%)

.70
.70

11 (78.6%)
2 (14.3%)
1 (7.1%)
31.3±1.9
175.2±9.3
96.9±8.6
54.4±4.5
119.1±12.4
111.4±10.3
24.4±4.5
14.2±1.2

10 (71.4%)
4 (28.6%)
0 (0%)
35.6±2.9
191.5±10.8
111.0±9.6
58.7±3.5
109.4±12.9
118.0±13.1
23.2±3.4
15.3±2.5

.65

RedCap software was used for data management and EXCEL for
data capture. SAS version 9.3 (SAS Institute, Cary, NC) was used for
analysis unless otherwise noted. Outliers and distributional properties were assessed by univariate analysis. Analysis of the PCB
congeners and DDE incorporated a log transformation. Baseline
differences between groups were analyzed using t test and Wilcoxon
rank sum or χ2 and Fisher’s Exact Test, as appropriate. Analysis of the
PCBs and DDE over the year used the fraction of their lipid-normalized
values at the first visit. Changes over the 1-year period between the
olestra and VO groups were assessed with a generalized linear
random-effects mixed model to account for the repeated nature of the
design. Of initial interest was the interaction between visit and group,
and if this was nonsignificant, the main effects model was examined.
Baseline values of the PCBs and DDE, as appropriate, were retained in
the model.
Elimination rate constants were determined from the natural
logarithms of these fractions (described below). Since we hypothesized that olestra crisps, relative to VO crisps and to each individual’s
own prior elimination rate of PCBs, would result in accelerated PCB
loss, comparisons were based on one-tailed tests. Individual regression analysis plots of the logarithms of the fractions versus time were
performed for each participant using Sigmaplot. Data are presented as
mean±standard error or geometric mean [95% confidence interval
(CI)], the latter reported when the data were skewed and a
logarithmic transformation was used for analysis. Analysis of the
PCBs included congener 153; the sum of congeners 153 180, 194,
196–203, 206 and 209 (higher-chlorinated congeners); and the total
of 37 congeners.
We used a first-order decay model assuming the elimination rate
of PCBs from the body was proportional to the amount in the body so
that dA/dt = −kt and Ln(A/Ao) = −kt, where Ao is the amount at time
0 and A is the amount remaining at time t. Time is expressed in years,
and the rate constant, k, as year−1. The natural logarithms of A/Ao
were plotted against time to determine the elimination rate constant
using linear regression analysis. Concentrations of lipid-normalized
PCBs obtained 4 to 6 years before the study and at time 0 for each
participant were used to calculate individual pretrial elimination
rates, and these rates were compared with each participant’s
elimination rate during the trial by paired t test. Each individual’s
pretrial elimination rate was also compared with the rate during the
trial by a one-tailed t test based on the standard error calculated from
the regression analysis of each individual’s change during the trial.
Values are presented as means and standard errors with significance
determined by Pb.05.
Half-lives cannot be calculated when elimination rate constants
are ≥0. Therefore, half-life estimates for each group were based on
the mean of the group’s elimination constant.

Data are presented as mean±S.E.M. or n (%). HDL, high-density lipoprotein.

3.1. Serum PCB levels
There were no statistically significant differences in total PCBs, PCB
153 or a group of higher-chlorinated congeners (153 180, 194, 196–
203, 206 and 209) at baseline between the olestra and VO groups. The
baseline values for total PCBs [geometric mean (95% CI)] as ng/g lipid
were 1448 (960, 2184) and 1341 (1001, 1978) for the olestra and VO
group, respectively. For the higher-chlorinated congeners, these
values were 709 (470, 1072) and 629 (475, 834); and for PCB, 153,
247 (144, 424) and 253 (168, 381), respectively.
The percent change from baseline was used to analyze the effect of
study group on serum PCBs (Fig. 1). The P value for the overall group
effect was .06. There was no statistically significant interaction of time
by group for PCB 153 or for total PCBs. The P value for the overall
group effect was .09. For the higher congeners, the interaction was not
statistically significant. The P value for the overall group effect was
.16. In all analyses, baseline level was retained as a covariate in the
model, although not statistically significant.
The total lipid-normalized serum PCBs [37 congeners; mean (95%
CI)] at the beginning of the trial were 1341 (1001, 1798) and 1448
(960, 2184) ng/g lipid (parts per billion) for the VO and olestra
groups, respectively. The concentrations on a wet weight basis were
8.4 (6.4, 11.2) and 9.3 (5.9, 14.8) ng/g serum for the VO and olestra
groups, respectively.
Elimination rate constants were calculated for the 37 congeners, a
group of higher-chlorinated congeners (PCBs 153 180, 194, 196–203,
206, 209) and PCB 153 alone. The higher-chlorinated congeners were
selected because of prevalence. Congener 153 was analyzed separately because of prevalence and its measurement in previous studies.
Serum PCB levels (ng/g lipid) measured 3.7 to 6.2 years (mean of 5.2
±0.1 years) before the trial for each individual were compared with

Table 2
BMI and serum measurements at the end of the 1-year trial and change from baseline

3. Results
The baseline characteristics of the groups and final visit measurements are presented in Table 1. Eleven of 14 participants in the olestra
group and 12 of 14 in the VO group completed the trial. One
participant in the olestra group started at the 4-month visit and
completed 8 months of treatment. There were no statistically
significant differences between groups at the initial visit (Table 1).
Changes from baseline from the participants who completed the trial
are presented in Table 2. There were no statistically significant
changes in BMI, consistent with the nutritional counseling that was
provided to maintain body weight during the trial.

.23
.26
.29
.47
.59
.70
.82
.68

VOlestra n=11 a

VO n=12

Final visit

Change from
baseline

Final visit

Change from
baseline

32.8±2.0
213.1±15.8
124.5±15.7
60.0±4.8
143.1±14.9
117.1±14.7
37.8±8.4
15.4±1.1

−0.07±0.31
35.7 b±8.8
28.3 b±8.0
5.9±3.3
8.5±16.7
7.4±9.3
9.9±6.1
0.32±1.00

35.0±3.3
190.0±11.2
109.4±10.0
59.9±4.3
104.0±9.1
105.5±9.6
31.6±6.7
13.0±1.1

−0.27±0.43
−1.4±6.0
0.42±5.11
−0.33±2.92
−6.8±8.1
−4.0±6.4
8.1±6.5
−2.5±1.8

Variable
BMI (kg/m2)
Total cholesterol (mg/dl)
LDL cholesterol (mg/dl)
HDL cholesterol (mg/dl)
Triglycerides (mg/dl)
Glucose (mg/dl)
Insulin (U/ml)
α-Tocopherol (μg/ml)
a
b

One subject in the olestra group started late, so final visit was at 8 months.
Statistically significant change from baseline.
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Table 3
Elimination rate constants for total PCBs (37 congeners), higher-chlorinated congeners
and PCB 153 in the VO and olestra groups for the pretrial and trial periods
Period

Measurement

Olestra (year−1)

VO (year−1)

Pretrial
Trial
Pretrial
Trial
Pretrial
Trial

Total PCBs
Total PCBs
Higher congeners
Higher congeners
PCB 153
PCB 153

−0.00864±0.0116
−0.0829a±0.0357
−0.00247±0.0110
−0.0809b±0.0356
−0.0282±0.0146
−0.1234c±0.0566

−0.0283±0.0096
−0.0413±0.0408
−0.0208±0.0062
−0.0296±0.0425
−0.02987±0.0084
−0.06546±0.0404

Letters indicate significant difference from pretrial value: a, P=.04; b, P=.03; c, P=.06.

change is presented for all PCBs during the trial for the VO and the
olestra groups in Fig. 2. During the trial, the VO group’s PCB
concentrations decreased to 96% of baseline, compared with a 1year decrease to 97% predicted by the pretrial measurements. The
olestra group’s concentration decreased to 92% of baseline, compared
with a predicted value of 99%. The decrease during the trial period
was significantly greater (Pb.05) than that predicted from the pretrial
elimination rate for the olestra group.

3.2. DDE
Of nine analyzed pesticides, the most prevalent was DDE, DDT’s
principal metabolite. Baseline lipid-normalized levels were elevated
relative to the general population, with 383 (171, 857) ng/g lipid in
the olestra group and 466 (279, 779) ng/g lipid in the VO group,

Fig. 1. Change from baseline for total PCBs (A), higher-chlorinated congeners (B) and
PCB 153 (C) for the olestra group (solid line) and the VO group (dotted line). Standard
errors are indicated by the vertical bars.

time 0 levels to calculate pretrial elimination rates. Rates were
calculated from values at 0, 0.33, 0.67 and 1.0 years (Table 3).
Half-lives were estimated from the mean elimination rate constants.
Total PCB half-lives were 80.2 and 24.5 years for the olestra and VO
groups, respectively. During the trial, these decreased to 8.4 and 16.8
years, respectively. Higher-chlorinated congener pretrial values of
280.1 and 33.4 years decreased to 8.6 and 23.4 years for the olestra and
VO groups, respectively, during the trial. These values for PCB 153 were
33.3 and 23.2 years during the pretrial period and 5.6 and 10.6 years
during the trial for the olestra and VO groups, respectively.
Percent change in body burden was calculated from elimination
rate constants for pretrial and trial periods. The predicted change
during the year of the trial was determined from the pretrial
elimination rate. This predicted change compared with the observed

Fig. 2. A comparison of the observed (dotted line) and predicted (solid line) changes in
total PCB body burden based on elimination rate constants calculated for the VO and
olestra groups. The decrease during the trial period was significantly greater than the
change predicted from the pretrial elimination rate for the olestra group.
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corresponding to the 75th to 90th percentile values for the US
population over 20 years [13]. The change in DDE levels during the
pretrial period was extremely variable. In the olestra group, there was
a mean increase of 84.3%±66.2% in DDE, and in the VO group, there
was an increase of 17.3%±46.6%. This high variance is consistent with
highly variable exposure during the pretrial period, which prevents a
comparison of the elimination rate during the pretrial with that
during the trial. During the trial, the mean elimination rate constant
for the DDE in the VO group was −0.053±0.0460 year−1, and that for
the olestra group was −0.175±0.064 year−1 (P=.067).
3.3. Changes from baseline
No difference in PCB concentrations was found between the olestra
and VO groups at baseline. For PCBs, the analysis examined the percent
change from baseline. The visit by group interaction was not
significant (P=.70), and the baseline term was borderline (P=·06).
The main effects model showed a significant group effect (P=.02), and
the baseline level was of borderline significance (P=.06). Baseline
(geometric mean, 95% CI, ng/g) concentrations of DDE were 383 (171,
857) and 466 (279, 779) for the olestra and VO groups, respectively. At
12 months, the concentrations were 84.1%±4.0% and 94.9%±3.6%
of the baseline values for the olestra and VO groups, respectively.
3.4. Adverse events and dropouts
Five participants dropped out of the study: two in the VO group
and three in the olestra group. In the VO group, one was due to weight
gain and diarrhea, and the other was due to hypertension. In the
olestra group, one was hospitalized during the first month of the trial
with diabetic complications, one was lost to follow up, and one had an
infection.
Four participants reported adverse events that may be related to
the trial. Two participants in the olestra group and one in the VO
group reported loose stools. For one participant in the olestra group,
crisp consumption was temporarily discontinued, the symptoms
stopped, and the participant continued the study regimen without
recurrence of loose stools. One participant in the olestra group
reported gas and bloating.
3.5. Compliance
Returned containers were checked and found to be consistent
with the diaries that were kept by the participants. The VO group
consumed 96.7%±1.2% of provided crisps; and the olestra group,
92.9%±2.2%.
4. Discussion
In this placebo-controlled trial, intervention with 15 g of olestra
per day for 1 year significantly reduced lipid-normalized PCBs more
than that predicted by pretrial measurements. These results are
consistent with olestra increasing the rate of reduction of the body
burden of PCBs, and they suggest a feasible intervention to reduce
associated health risks.
There was high variance in the response to olestra. For example,
total PCB levels in participants 13 and 19 decreased by 27% and 25%,
respectively, during the trial, yielding half-lives of 2.2 and 2.4 years,
values that are markedly greater than their respective reductions of
0.2% and 0.9% per year in the pretrial period. PCB elimination rates
during the trial were significantly different from pretrial rates (Pb.05)
for participants 13 and 19 and for 5 of 11 olestra group participants. In
the VO group, the rates during the trial differed from pretrial rates in
only 2 of 12 participants.

487

Wide variations in serum concentration and elimination rates are
typical of PCB biomonitoring. PCB half-life estimates varied considerably within treatment groups, among pretest and in-test estimates,
as well as when compared between pretest and in-test estimates.
Given these realities, we acknowledge that even more variability is
likely to be observed when determining half-lives based on a 1-year
timeframe for biomonitoring (as done in this study) compared to
estimations based on longer timeframes. This analytical consideration
indicates the value of a longer trial.
A large adipose mass limits the proportion of the body’s PCBs that
are available to the blood for direct intestinal excretion. The half-life
of 2,3,7,8-tertrachlorodibenzodioxin (TCDD) has been shown to
double when body fat increased from 20 to 30 kg, suggesting that
an individual will more likely respond to olestra when the adipose
tissue compartment is small [15]. Consistent with this possibility is
the observation that the BMIs of participants 13 and 19, who
experienced large increases in elimination rates, were 24.1 and
27.6, respectively, which were less than that of the group mean
(32·8) and were maintained during the study. It seems likely that
health benefits that may result will be determined by the mass of
adipose tissue that stores these compounds. A large adipose depot
may limit the fraction of PCBs that are available for removal through
interruption of enterohepatic circulation.
Ideally, this trial would have measured adipose tissue mass
throughout the study along with adipose concentrations of PCBs so
that body burden would be the product of adipose tissue mass and
PCB concentration. However, given this trial’s exploratory nature and
our concerns about participant compliance, we opted to measure
serum PCB concentrations. It has been shown that lipid-normalized
serum organochlorine concentrations are good approximations of
the adipose tissue levels [16,17]. Our “window” on PCB body burden
was PCBs in the blood serum lipid fraction coupled with constant
body weight.
The VO was not an inert placebo since it provided dietary fat, and
this might have accounted for the observed decrease in the half-life of
blood PCBs in some VO individuals. Partial malabsorption of dietary
fat can reduce the absorption of organochlorines in enterohepatic
circulation [18].
Previous studies of the effects of olestra on organochlorine
metabolism in humans have been reported. Blood levels of organochlorines were measured during 3 months of weight loss to
determine olestra’s effect on increases in blood organochlorines
that accompany weight loss [19]. In that trial, olestra altered βhexachlorocyclohexane but not other organochlorines. The subjects
lost body weight during that trial so that total organochlorine body
burdens were not measured. Geusau et al. reported a “relatively small
effect” of olestra on another organochlorine, the dioxin TCDD, in two
subjects [20]. The small effect of olestra was attributed to the short
half-life of TCDD and poor compliance with the olestra dose during
the 3-year trial. Moser and McLachlan reported enhancement of fecal
excretion rates of dioxin when olestra was fed to four subjects [21].
Increases in total and low-density lipoprotein (LDL) cholesterol in
the olestra group at 12 months observed during the trial were
unexpected since olestra has previously been reported to modestly
reduce these levels [22–24]. There was not, however, a significant
increase in these lipids based on regression analysis of their
concentration over time.
Minimal risk resulted from treatment with 15 g/day of olestra.
Modest and transient gastrointestinal effects were reported by only
two participants in the olestra group. With the regimen of a daily
normal multivitamin supplement, there was no effect on fat-soluble
vitamin status based on serum α-tocopherol levels.
Our findings suggest that nonabsorbable dietary lipid can hasten
the removal of PCBs. Because the trial was exploratory in nature, the
sample size was small and the duration was short in terms of PCB half-
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lives. Finally, we do not know if exposure to PCBs in foods continued
in some individuals during the trial.

[8]

5. Conclusion
Interruption of enterohepatic circulation of PCBs and their
metabolites by a nonabsorbable lipid can reduce body burdens of
PCBs. Modest, transient adverse events related to the regimen were
observed, consistent with a low risk-to-benefit ratio. Extension of this
study to a cohort with normal ranges of BMI and to subjects who are
undergoing weight loss will expand our understanding of this novel
and potentially useful treatment strategy.
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